Clinical trial · Interventional
Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion
NCT02657460CI-TRIAL-00037300unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is to investigate the anticancer effect and the related immunological mechanism of MTX-ATMPs in the treatment of malignant pleural effusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| tumor derived microparticles | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MTX-ATMPs
- description
- methotrexate-autologous tumor derived microparticles
- interventionNames
- Biological: tumor derived microparticles
- type
- SHAM_COMPARATOR
- label
- cisplatin
- description
- Cisplatin is a traditional treatment for lung cancer
- interventionNames
- Drug: cisplatin
Primary outcomes (1)
- measure
- Pleural effusions volume
- timeFrame
- four weeks
Secondary outcomes (13)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. The diagnosis of lung cancer and malignant pleural effusion was confirmed by pathology and / or pleural fluid cytology; 2. The routine surgery or systemic radio/chemotherapy was ineffective, the MPE relapsed, or routine treatment therapy was given up by self-causes; 3. stable vital sign with KPS(Karnofsky Performance Status) index more than 60; 4. 18-70 years old; 5. normal haematopoietic function of bone marrow, no hemorrhagic tendency, blood routine test: HGB\>=100g/L, WBC\>4.0\*10\^9/L, PLT\>80\*10\^9/L, serum ALT, AST within 2 times upper limit of normal, BUN within 1.5 time upper limit of normal, creatinine within normal range, normal EKG; 6. agreed to participate in the study and sign an informed consent; 7. without other severe comorbidities. Exclusion Criteria: 1. lactating or pregnant patients; 2. allergy to multiple drugs; 3. with other severe comorbidities or psychological diseases; 4. severe infection; 5. participation in other clinical trials within the recent three months.
References
Publications (0)
Data not yet available
No reference posted for this study.